One deal will see Philips' solution used to improve cancer patient outcomes while the other will beef up its ability to interpret data from oncology tests.
N-of-One will interpret data from HemeSeq profiles for acute myeloid leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and other cancers.
N-of-One will provide treatment strategies and clinical trial opportunities for patients based on Inivata's ctDNA liquid biopsy test.
N-of-One will use the funds to develop new oncology clinical decision support solutions, and to expand its sales and marketing efforts.
N-of-One will identify the most relevant therapeutic options for each patient tested with Admera's 64-gene oncology panel.
N-of-One will provide Macrogen with clinical interpretation services for its clinical next-generation sequencing-based cancer panels.
N-of-One will provide clinical and scientific evidence that supports personalized treatment recommendations made on the basis of WuXi Nextcode's tumor-normal sequence interpretation.
N-of-One has launched a new service called PrecisionInsights through which it will provide clinical interpretation for small, targeted gene panels.
Under the terms of the agreement, N-of-One will provide clinical interpretation services for samples sequenced on a 50-gene hot-spot solid tumor panel.
N-of-One will provide clinical interpretation for GenomiCare's next-generation sequencing-based tumor exome profiling test in China.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.